Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Credit Human Share Certificates made our list of the best five-year CD accounts thanks to its competitive APY and relatively low minimum deposit requirement. We like that Credit Human Share ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

If you're interested in exploring more stocks under $5 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Searching for quality stocks under $5 is a lot ...

Contractors got information on two major projects involving the East Bank Development. TDOT wants to fast track both projects.